Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ritivixibat - Albireo Pharma

Next Previous
Drug Profile

Ritivixibat - Albireo Pharma

Alternative Names: A-3907; IPN-60250

Latest Information Update: 22 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Albireo Pharma
  • Developer Albireo Pharma; Ipsen
  • Class 2 ring heterocyclic compounds; Anti-inflammatories; Antifibrotics; Hepatoprotectants; Phenyl ethers; Propionic acids; Sulfides; Sulfonamides; Thiazepines
  • Mechanism of Action Sodium-bile acid cotransporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Primary sclerosing cholangitis
  • Phase I Primary biliary cirrhosis
  • No development reported Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 04 May 2026 Albireo terminates phase-II clinical trials in Primary sclerosing cholangitis (In the elderly, In adults) in France, Italy, Poland and Spain (PO) due to sponsors decision (NCT05642468)
  • 16 Sep 2025 Chemical structure information added.
  • 31 Jul 2025 Albireo completes phase-II clinical trials in Primary sclerosing cholangitis (In the elderly, In adults) in France, Italy, Poland and Spain (PO) (NCT05642468)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top